DIKUL - logo
Narodna in univerzitetna knjižnica, Ljubljana (NUK)
Naročanje gradiva za izposojo na dom
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi
  • Izbira peroralnega antidiabetika za zdravljenje sladkorne bolezni tipa 2 = Selection of an oral antidiabetic for treatment of type 2 diabetes
    Mrevlje, Franc, 1946-
    Type 2 diabetes is a chronic metabolic disorder that results from defects in insulin secretion and insulin action, which is diminished because of insulin resistance in peripheral tissues. One of the ... objectives in management of type 2 diabetes beside other atherogenic risk factors is to maintain glycemia in anacceptable range, thus minimizing the risk of development or progression of chronic vascular damage. When non-pharmacological measures fail to maintain adequate glycemia, oral antidiabetic treatment is initiated. Oral pharmacological agents include sulfonylureas, biguanide metformin, thiazolidinediones (rosiglitazone, pioglitazone), short-acting insulin secretagogues (repaglinide, nateglinide) and alpha-glucosidase inhibitors (acarbose, miglitol). Pharmacological differences among them are important in deciding which and when to choose in specific patients. Each of them can be used in monotherapy, or they can be combined in stepwise fashion (a traditional model) to achieve optimal glycemic control. Diabetes is a progressive disease, and in five to ten years oral antidiabetic treatment become insufficient. At that time insulin treatment, in combination with oral agents or insulin alone, must be initiated.
    Vir: Medicinski razgledi. Supplement. - ISSN 0353-3484 (Letn. 41, supl. 1, feb. 2002, str. 11-16)
    Vrsta gradiva - članek, sestavni del
    Leto - 2002
    Jezik - slovenski
    COBISS.SI-ID - 14852057

vir: Medicinski razgledi. Supplement. - ISSN 0353-3484 (Letn. 41, supl. 1, feb. 2002, str. 11-16)

loading ...
loading ...
loading ...

Vnos na polico